Digitoxin in heart failure with reduced ejection fraction according to atrial fibrillation status: the DIGIT-HF trial

“Although the formal interaction between [AFib] and treatment did not reach significance, the larger absolute risk reductions and lower [NNT] in the [AFib] subgroup ... suggest that digitoxin may confer particular benefit in this high-risk population.”